- Home
- YMAB
as 07-26-2024 4:00pm EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 542.8M | IPO Year: | 2018 |
| Target Price: | $19.00 | AVG Volume (30 days): | 297.8K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.60 - $20.90 | Next Earning Date: | 08-08-2024 |
| Revenue: | $84,499,000 | Revenue Growth: | 12.62% |
| Revenue Growth (this year): | 16.29% | Revenue Growth (next year): | 21.24% |
Stock Insider Trading Activity of Y-mAbs Therapeutics Inc. (YMAB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ber Gerard | YMAB | Director | Jun 10 '24 | Sell | $12.00 | 722 | $8,664.00 | 1,608 | SEC Form 4 |
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Jun 10 '24 | Sell | $12.03 | 35,000 | $421,050.00 | 197,681 | SEC Form 4 |
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Jun 10 '24 | Sell | $12.00 | 35,000 | $420,000.00 | 162,681 | SEC Form 4 |
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | May 21 '24 | Sell | $12.00 | 25,000 | $300,000.00 | 240,032 | SEC Form 4 |
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | May 21 '24 | Sell | $13.00 | 7,351 | $95,563.00 | 232,681 | SEC Form 4 |
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Mar 5 '24 | Sell | $16.44 | 3,900 | $64,116.00 | 158,700 | SEC Form 4 |
| Rajah Vignesh | YMAB | SVP & CHIEF MEDICAL OFFICER | Mar 5 '24 | Sell | $16.53 | 1,711 | $28,282.83 | 33,889 | SEC Form 4 |
| Smith Susan Laura | YMAB | SVP & CHIEF COMMERCIAL OFFICER | Mar 5 '24 | Sell | $16.55 | 1,682 | $27,837.10 | 33,918 | SEC Form 4 |
| WG Biotech ApS | YMAB | Director | Dec 11 '23 | Buy | $6.85 | 6,455 | $44,231.60 | 4,559,233 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Dec 11 '23 | Buy | $6.85 | 6,455 | $44,231.60 | 4,559,233 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Dec 7 '23 | Buy | $6.50 | 6,183 | $40,189.50 | 4,431,412 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Dec 7 '23 | Buy | $6.99 | 18,503 | $129,378.53 | 4,449,915 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Dec 7 '23 | Buy | $7.01 | 102,863 | $720,843.33 | 4,552,778 | SEC Form 4 |
| WG Biotech ApS | YMAB | Director | Dec 7 '23 | Buy | $6.50 | 6,183 | $40,189.50 | 4,431,412 | SEC Form 4 |
| WG Biotech ApS | YMAB | Director | Dec 7 '23 | Buy | $6.99 | 18,503 | $129,378.53 | 4,449,915 | SEC Form 4 |
| WG Biotech ApS | YMAB | Director | Dec 7 '23 | Buy | $7.01 | 102,863 | $720,843.33 | 4,552,778 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Nov 29 '23 | Buy | $5.97 | 51,837 | $309,477.26 | 4,425,229 | SEC Form 4 |
| WG Biotech ApS | YMAB | Director | Nov 27 '23 | Buy | $5.49 | 62,516 | $343,019.04 | 4,342,721 | SEC Form 4 |
| WG Biotech ApS | YMAB | Director | Nov 27 '23 | Buy | $5.81 | 30,671 | $178,275.19 | 4,373,392 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Nov 27 '23 | Buy | $5.49 | 62,516 | $343,019.04 | 4,342,721 | SEC Form 4 |
| Wedell-Wedellsborg Johan | YMAB | Director | Nov 27 '23 | Buy | $5.81 | 30,671 | $178,275.19 | 4,373,392 | SEC Form 4 |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
MT Newswires
25 days ago
Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO
GlobeNewswire
25 days ago
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
MT Newswires
a month ago
Truist Initiates Y-mAbs Therapeutics at Buy With $21 Price Target, Calls Radioimmunotherapy Platform 'Undervalued'
GuruFocus.com
a month ago
A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
Energy Global
a month ago
ANDRITZ to equip new Silvan hydropower plant in Türkiye
USA TODAY
a month ago
Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
Business Wire
a month ago
Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.